Answers are grounded in this paper and cite their sources.
Animal experimental study demonstrates that baclofen shifts colon tumors from malignant adenocarcinomas to benign adenomas in rats, suggesting GABAB receptor activation limits tumor progression.
The effects of the gamma-amino-n-butyric acid (GABA)A receptor agonist muscimol, and the GABAB receptor agonist baclofen, on colon carcinogenesis induced by azoxymethane in Wistar rats were tested. Administration of either muscimol or baclofen had no influence on the incidence of colon tumors at week 30. However, almost all the colon tumors that developed in rats treated with baclofen were adenomas, whereas in the control group the tumors were mainly adenocarcinomas. In contrast, administration of muscimol did not affect the histological types of the colon tumors. These findings indicate that baclofen inhibits the growth of colon tumors via the GABAB receptor.
No takes yet. Share an insight, caveat, or question.
Tatsuta et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: